Replies to post #299542 on Bioelectronics Corp (BIEL)

[JustGoDeep]

~~~~~~~ BABBLE ~~~~~~~

[Probity]

I disagree Steve. BIEL was at a point where money was presented as being an ongoing concern. If that is true, then who the upper hand at that negotiation table? KT with a long enough track record of raking in millions or BIEL with one profitable quarter a while back and last quarter a 40% drop, even given a 975,000 surprise? There is something to be said about pleasant surprises/sales having a track record BEFORE going to negotiations.

No my friend, I am of the opinion that there were some internal missteps, that ALL companies go through at one point or another, and then external pressures all talked about here to no end. And it was a world of hurt.

I have been on four negotiation teams in the past, and the first thing you do is absolute thorough due diligence on your prospect, their products, a SWOT analysis (Strengths, Weaknesses, Opportunities and Threats) for ones own company regarding a partnership, and even from the lens of looking in at the other company, yet most importantly, determining who needs who more and to what degree. Not an all inclusive list by any means.

It is shark tank my friend. KT was the shark.

All imo.

[GetSeriousOK]

BIEL consists of country bumpkins housed in an incubator.

These bumpkins have no experience negotiating or marketing. Andy's failures with retailers and Dr. Scholl's are well documented. The minor-league baseball player was brought on to get the product into retail outlets and he failed. The clinical studies by the Koneru Brothers and Dr. Eppley were inept. Luckily, a couple of independent researchers chose to study the ActiPatch and publish the clinical results -- otherwise BIEL wouldn't have FDA full-body clearance.

KT Tape and Donjoy didn't spend much money developing their ActiPatch products and they aren't spending much money marketing their ActiPatch products. If the ActiPatch doesn't sell, they don't lose much.

The pandemic was the PERFECT opportunity to sell pain relief products online but BIEL chose to sit back in their easy chairs and let others do all the work. Result: poor (and declining) revenues, increased debt, share price .0006

The Synergy deal not only isn't finalized -- it won't be finalized until they get regulatory clearancein what, six countries? And if/when it gets finalized, it's not a guaranteed sale of hundreds of thousands of units -- The number sold depends on whether Synergy can convince doctors to prescribe RecoveryRx, something that no other distributor has been able to do in the 12 years RecoveryRx has been marketed.

Maybe Kelly will sell out to an experienced biotech that knows how to market devices. That's the only way the ActiPatch succeeds. Kelly must be thinking EVERY DAY about cashing out. Life is too short to waste time fumblin' bumblin' and stumblin' like this.